patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_103324 | REC_0010001 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 13.2 | 75 | female | 1 | 17 | 4.9 | 1 | pembrolizumab 200 mg q3w | 15 | true | MSI-H | 2026-03-15T05:35:59.334337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775183 | REC_0010002 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 6.3 | 69 | male | 0 | 12 | 6.9 | 5 | osimertinib 80 mg daily | 4.4 | false | MSS | 2026-03-15T05:35:59.334624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215366 | REC_0010003 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 17.6 | 86 | male | 2 | 16 | 8.1 | 7 | alectinib 600 mg BID | 11.7 | true | MSI-H | 2026-03-15T05:35:59.334900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104326 | REC_0010004 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 8.9 | 79 | male | 1 | 21 | 5.3 | 1 | entrectinib 600 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:59.335171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208747 | REC_0010005 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 5.5 | 67 | female | 1 | 15 | 6.8 | 7 | osimertinib 80 mg daily | 10.9 | true | MSS | 2026-03-15T05:35:59.335450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860680 | REC_0010006 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.8 | 71 | female | 1 | 36 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 18.3 | true | MSS | 2026-03-15T05:35:59.335738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781049 | REC_0010007 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 16.1 | 65 | male | 0 | 8 | 4.5 | 4 | osimertinib 80 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:59.336036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901993 | REC_0010008 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 10.6 | 67 | female | 0 | 16 | 6.6 | 8 | sotorasib 960 mg daily | 8.4 | true | MSI-H | 2026-03-15T05:35:59.336406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324645 | REC_0010009 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 5.8 | 61 | female | 1 | 17 | 6.4 | 2 | alectinib 600 mg BID | 17.1 | false | MSS | 2026-03-15T05:35:59.336721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881357 | REC_0010010 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 34 | 6.8 | 65 | female | 1 | 6 | 5.4 | 1 | entrectinib 600 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:59.337015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256756 | REC_0010011 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 18.2 | 70 | female | 2 | 9 | 6.5 | 2 | alectinib 600 mg BID | 19.5 | true | MSS | 2026-03-15T05:35:59.337479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180372 | REC_0010012 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 13.8 | 53 | female | 0 | 14 | 6 | 6 | pembrolizumab 200 mg q3w | 6.9 | false | MSI-H | 2026-03-15T05:35:59.337803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933267 | REC_0010013 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10 | 75 | female | 1 | 14 | 5.2 | 6 | alectinib 600 mg BID | 17.1 | false | MSS | 2026-03-15T05:35:59.338106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395824 | REC_0010014 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.4 | 51 | female | 0 | 72 | 3.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:35:59.338412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980335 | REC_0010015 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 4.9 | 49 | female | 0 | 42 | 5.4 | 2 | pembrolizumab 200 mg q3w | 5.4 | false | MSS | 2026-03-15T05:35:59.338715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629581 | REC_0010016 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 36 | 20 | 77 | female | 2 | 19 | 6 | 6 | alectinib 600 mg BID | 9.2 | false | MSS | 2026-03-15T05:35:59.339005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596156 | REC_0010017 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.6 | 71 | female | 2 | 35 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 23.1 | true | MSS | 2026-03-15T05:35:59.339277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105996 | REC_0010018 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 5 | 58 | male | 1 | 24 | 7 | 1 | osimertinib 80 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:59.339565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_523308 | REC_0010019 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 14.2 | 58 | male | 1 | 9 | 6 | 2 | osimertinib 80 mg daily | 17.1 | false | MSI-H | 2026-03-15T05:35:59.339851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367092 | REC_0010020 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 31 | 6.1 | 47 | male | 0 | 12 | 5.5 | 0 | osimertinib 80 mg daily | 42.3 | false | MSS | 2026-03-15T05:35:59.340185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354357 | REC_0010021 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.2 | 71 | female | 2 | 25 | 5.9 | 3 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:35:59.340488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329370 | REC_0010022 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 15.8 | 69 | female | 0 | 19 | 6.2 | 7 | osimertinib 80 mg daily | 7.8 | false | MSI-H | 2026-03-15T05:35:59.340780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696890 | REC_0010023 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.4 | 65 | female | 0 | 53 | 5.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:35:59.341082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871187 | REC_0010024 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.5 | 74 | female | 2 | 49 | 3.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.7 | true | MSS | 2026-03-15T05:35:59.341509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460304 | REC_0010025 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 9 | 3.7 | 68 | female | 1 | 39 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.8 | true | MSS | 2026-03-15T05:35:59.341847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939291 | REC_0010026 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.2 | 55 | female | 0 | 14 | 5.3 | 2 | sotorasib 960 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:59.342157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215744 | REC_0010027 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.3 | 67 | male | 0 | 12 | 5.8 | 3 | sotorasib 960 mg daily | 5.4 | false | MSS | 2026-03-15T05:35:59.342462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425749 | REC_0010028 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.7 | 64 | female | 0 | 39 | 6.7 | 0 | pembrolizumab 200 mg q3w | 30.7 | false | MSS | 2026-03-15T05:35:59.342746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410194 | REC_0010029 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 7.7 | 68 | female | 1 | 24 | 4.6 | 3 | osimertinib 80 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:59.343062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581049 | REC_0010030 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.4 | 64 | male | 1 | 18 | 4 | 6 | entrectinib 600 mg daily | 6.9 | false | MSI-H | 2026-03-15T05:35:59.343395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994810 | REC_0010031 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 9.4 | 60 | female | 1 | 23 | 6 | 0 | entrectinib 600 mg daily | 13.5 | true | MSS | 2026-03-15T05:35:59.343691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844606 | REC_0010032 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 25 | 71 | female | 1 | 21 | 5.5 | 4 | alectinib 600 mg BID | 5.4 | false | MSS | 2026-03-15T05:35:59.343968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801721 | REC_0010033 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13.2 | 71 | male | 1 | 25 | 2.5 | 6 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:59.344357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756222 | REC_0010034 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 33 | 7.8 | 67 | male | 0 | 62 | 5 | 2 | pembrolizumab 200 mg q3w | 16.1 | true | MSS | 2026-03-15T05:35:59.344714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179688 | REC_0010035 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 16.9 | 66 | female | 0 | 11 | 6.2 | 6 | sotorasib 960 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:59.344986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877781 | REC_0010036 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 9.5 | 51 | female | 0 | 14 | 7.8 | 5 | alectinib 600 mg BID | 10.7 | true | MSS | 2026-03-15T05:35:59.345415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386196 | REC_0010037 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 36 | 9.7 | 69 | female | 1 | 23 | 6.9 | 1 | osimertinib 80 mg daily | 38.5 | false | MSS | 2026-03-15T05:35:59.346158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227957 | REC_0010038 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 5.3 | 51 | male | 0 | 14 | 5 | 8 | sotorasib 960 mg daily | 16.5 | false | MSS | 2026-03-15T05:35:59.346580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478132 | REC_0010039 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 8.6 | 67 | female | 0 | 23 | 5.1 | 1 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:59.346918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801524 | REC_0010040 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.4 | 64 | female | 1 | 19 | 6.3 | 5 | pembrolizumab 200 mg q3w | 13.4 | false | MSS | 2026-03-15T05:35:59.347206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830648 | REC_0010041 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 8.2 | 87 | female | 2 | 17 | 5.3 | 2 | pembrolizumab 200 mg q3w | 15.7 | true | MSS | 2026-03-15T05:35:59.347479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133804 | REC_0010042 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 4.5 | 59 | male | 1 | 13 | 5.4 | 8 | pembrolizumab 200 mg q3w | 15.2 | true | MSS | 2026-03-15T05:35:59.347754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652251 | REC_0010043 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 3.6 | 72 | female | 1 | 31 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 28.3 | true | MSS | 2026-03-15T05:35:59.348020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888133 | REC_0010044 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 9.9 | 72 | female | 1 | 13 | 5.8 | 6 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.348357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838024 | REC_0010045 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.9 | 55 | male | 1 | 16 | 6.2 | 3 | sotorasib 960 mg daily | 8.9 | false | MSI-H | 2026-03-15T05:35:59.348639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881271 | REC_0010046 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.2 | 84 | male | 3 | 8 | 5.8 | 7 | alectinib 600 mg BID | 14.2 | false | MSI-H | 2026-03-15T05:35:59.348921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647244 | REC_0010047 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 9.1 | 66 | male | 1 | 9 | 6 | 5 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:59.349210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295680 | REC_0010048 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 12.5 | 70 | female | 1 | 12 | 8.2 | 2 | osimertinib 80 mg daily | 23.7 | false | MSS | 2026-03-15T05:35:59.349533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974581 | REC_0010049 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 15.8 | 64 | male | 0 | 18 | 4.6 | 7 | alectinib 600 mg BID | 14.2 | false | MSI-H | 2026-03-15T05:35:59.349829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733315 | REC_0010050 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 11.9 | 76 | female | 1 | 20 | 4.7 | 8 | pembrolizumab 200 mg q3w | 7.3 | false | MSS | 2026-03-15T05:35:59.350237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922095 | REC_0010051 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.1 | 58 | male | 1 | 21 | 6.1 | 6 | alectinib 600 mg BID | 11.8 | true | MSI-H | 2026-03-15T05:35:59.350554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615846 | REC_0010052 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.2 | 67 | female | 0 | 26 | 4.2 | 7 | sotorasib 960 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:59.350863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405069 | REC_0010053 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 12.4 | 74 | female | 0 | 6 | 3.6 | 5 | osimertinib 80 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:35:59.351207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975384 | REC_0010054 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.3 | 61 | male | 0 | 32 | 6.6 | 5 | pembrolizumab 200 mg q3w | 13.4 | true | MSS | 2026-03-15T05:35:59.351485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369428 | REC_0010055 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 13.7 | 62 | female | 1 | 18 | 4.2 | 4 | sotorasib 960 mg daily | 7.9 | false | MSI-H | 2026-03-15T05:35:59.351763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294183 | REC_0010056 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 16.6 | 66 | female | 0 | 13 | 7.8 | 4 | entrectinib 600 mg daily | 5.4 | false | MSS | 2026-03-15T05:35:59.352029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645113 | REC_0010057 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.4 | 77 | female | 2 | 21 | 4.9 | 5 | pembrolizumab 200 mg q3w | 18.8 | true | MSS | 2026-03-15T05:35:59.352444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638106 | REC_0010058 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.3 | 46 | female | 0 | 20 | 7.3 | 4 | osimertinib 80 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:59.352746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504969 | REC_0010059 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 9.9 | 70 | female | 2 | 17 | 7 | 1 | sotorasib 960 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:59.353023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572635 | REC_0010060 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.1 | 71 | female | 2 | 13 | 6.1 | 8 | sotorasib 960 mg daily | 20.4 | false | MSS | 2026-03-15T05:35:59.353288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651855 | REC_0010061 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 16.4 | 57 | male | 1 | 9 | 6 | 3 | entrectinib 600 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:35:59.353551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575546 | REC_0010062 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 3.3 | 76 | female | 2 | 42 | 3.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 19 | false | MSS | 2026-03-15T05:35:59.353804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150111 | REC_0010063 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 3.4 | 75 | female | 0 | 21 | 7.8 | 6 | pembrolizumab 200 mg q3w | 10 | false | MSS | 2026-03-15T05:35:59.354203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791332 | REC_0010064 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 3.3 | 71 | male | 1 | 12 | 6.1 | 6 | alectinib 600 mg BID | 5.6 | true | MSS | 2026-03-15T05:35:59.354475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187354 | REC_0010065 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 14.9 | 64 | female | 1 | 3 | 4.7 | 1 | osimertinib 80 mg daily | 14.4 | true | MSI-H | 2026-03-15T05:35:59.354742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414951 | REC_0010066 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 22 | 12.9 | 61 | female | 1 | 14 | 4.3 | 0 | entrectinib 600 mg daily | 34.1 | false | MSI-H | 2026-03-15T05:35:59.355001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117014 | REC_0010067 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.2 | 71 | female | 1 | 11 | 7.5 | 5 | pembrolizumab 200 mg q3w | 13.7 | true | MSS | 2026-03-15T05:35:59.355255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771999 | REC_0010068 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.1 | 69 | female | 0 | 13 | 5.9 | 4 | osimertinib 80 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:35:59.355519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995496 | REC_0010069 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 10.7 | 83 | female | 2 | 13 | 4.7 | 6 | osimertinib 80 mg daily | 18.8 | false | MSI-H | 2026-03-15T05:35:59.355790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811502 | REC_0010070 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 13.6 | 55 | female | 0 | 14 | 5.6 | 2 | osimertinib 80 mg daily | 17 | true | MSI-H | 2026-03-15T05:35:59.356058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738299 | REC_0010071 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 18.6 | 66 | female | 0 | 10 | 4.6 | 7 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:59.356575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625514 | REC_0010072 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 11.1 | 69 | female | 1 | 13 | 6.8 | 5 | osimertinib 80 mg daily | 17.9 | true | MSI-H | 2026-03-15T05:35:59.356911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431821 | REC_0010073 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.3 | 81 | female | 2 | 2 | 5.2 | 2 | osimertinib 80 mg daily | 20.6 | true | MSI-H | 2026-03-15T05:35:59.357233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297346 | REC_0010074 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.2 | 63 | male | 0 | 32 | 6.9 | 7 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:35:59.357535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985457 | REC_0010075 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 9.3 | 67 | female | 0 | 14 | 5.9 | 1 | sotorasib 960 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:59.357837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150938 | REC_0010076 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 10.1 | 59 | male | 0 | 21 | 6.1 | 3 | alectinib 600 mg BID | 8.4 | false | MSI-H | 2026-03-15T05:35:59.358343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652832 | REC_0010077 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 16.9 | 77 | female | 1 | 17 | 4.8 | 5 | entrectinib 600 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:35:59.358738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221949 | REC_0010078 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 33 | 8.7 | 73 | female | 2 | 43 | 6.1 | 1 | pembrolizumab 200 mg q3w | 30 | true | MSS | 2026-03-15T05:35:59.359070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273118 | REC_0010079 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 8.4 | 69 | female | 1 | 23 | 3.6 | 3 | alectinib 600 mg BID | 8.7 | false | MSS | 2026-03-15T05:35:59.359410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377813 | REC_0010080 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 15.5 | 57 | male | 1 | 2 | 5.1 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.359747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377386 | REC_0010081 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6 | 55 | male | 1 | 52 | 6.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:35:59.360136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977320 | REC_0010082 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 21.3 | 59 | male | 0 | 21 | 6.2 | 8 | sotorasib 960 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:59.360541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901560 | REC_0010083 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 14 | 61 | female | 0 | 16 | 5.8 | 1 | osimertinib 80 mg daily | 19.7 | true | MSI-H | 2026-03-15T05:35:59.360909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132393 | REC_0010084 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 18 | 12.9 | 64 | male | 1 | 17 | 5.1 | 0 | osimertinib 80 mg daily | 22.1 | false | MSS | 2026-03-15T05:35:59.361266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391309 | REC_0010085 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 8.1 | 79 | female | 2 | 18 | 6.8 | 3 | sotorasib 960 mg daily | 22.7 | false | MSS | 2026-03-15T05:35:59.361599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758518 | REC_0010086 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 13.6 | 68 | female | 1 | 19 | 3.2 | 1 | alectinib 600 mg BID | 23.3 | true | MSS | 2026-03-15T05:35:59.361963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535285 | REC_0010087 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 10.9 | 73 | male | 2 | 2 | 7.6 | 1 | alectinib 600 mg BID | 14.8 | false | MSS | 2026-03-15T05:35:59.362347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687620 | REC_0010088 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12 | 67 | male | 1 | 12 | 5.1 | 1 | sotorasib 960 mg daily | 16.4 | false | MSI-H | 2026-03-15T05:35:59.362689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845497 | REC_0010089 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 37 | 11.7 | 79 | female | 1 | 15 | 5.9 | 6 | pembrolizumab 200 mg q3w | 5 | false | MSI-H | 2026-03-15T05:35:59.363203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697683 | REC_0010090 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.8 | 65 | female | 1 | 15 | 7.1 | 7 | alectinib 600 mg BID | 9 | true | MSI-H | 2026-03-15T05:35:59.363549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264345 | REC_0010091 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.4 | 63 | female | 0 | 48 | 7.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.9 | false | MSS | 2026-03-15T05:35:59.363874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696964 | REC_0010092 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 14.6 | 59 | male | 1 | 13 | 6.4 | 6 | pembrolizumab 200 mg q3w | 12.3 | false | MSI-H | 2026-03-15T05:35:59.364208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612692 | REC_0010093 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 10.9 | 67 | female | 0 | 8 | 5 | 1 | entrectinib 600 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:59.364487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605524 | REC_0010094 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15.6 | 67 | male | 1 | 20 | 7.1 | 8 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:59.364777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898404 | REC_0010095 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 5.3 | 82 | female | 2 | 13 | 6 | 0 | carboplatin + paclitaxel + pembrolizumab | 39.2 | true | MSS | 2026-03-15T05:35:59.365029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571433 | REC_0010096 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 18.2 | 65 | male | 0 | 15 | 5.3 | 8 | entrectinib 600 mg daily | 6.8 | false | MSI-H | 2026-03-15T05:35:59.365302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767000 | REC_0010097 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.9 | 56 | female | 0 | 16 | 7 | 6 | entrectinib 600 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:59.365552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398961 | REC_0010098 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.6 | 85 | male | 0 | 5 | 6.4 | 4 | osimertinib 80 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:35:59.365818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678903 | REC_0010099 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 20 | 74 | female | 1 | 12 | 5 | 1 | entrectinib 600 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:35:59.366079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185091 | REC_0010100 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 16.3 | 75 | male | 2 | 23 | 4 | 1 | osimertinib 80 mg daily | 20.4 | false | MSI-H | 2026-03-15T05:35:59.366342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.